Evidence map›Paper›PMID 22003095›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2012

Dopamine inhibits pulmonary edema through the VEGF-VEGFR2 axis in a murine model of acute lung injury.

Pawan K Vohra, Luke H Hoeppner, Gunisha Sagar, Shamit K Dutta, Sanjay Misra, Rolf D Hubmayr, Debabrata Mukhopadhyay

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Dopamine D2 Receptor Agonists as Modulators of VEGF-A-Driven Angiogenesis: Mechanisms, Clinical Evidence, and Translational Opportunities.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  5. Dopamine DCell death & disease · 2025
    Article
  6. Review
  7. Article
  8. Anti-Inflammatory Effects of Peripheral Dopamine.International journal of molecular sciences · 2023
    Review
  9. Article
  10. Molecular profiling of the stroke-induced alterations in the cerebral microvasculature reveals promising therapeutic candidates.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  11. ADAM10-a "multitasker" in sepsis: focus on its posttranslational target.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023
    Review
  12. Article
  13. Where Is Dopamine and how do Immune Cells See it?: Dopamine-Mediated Immune Cell Function in Health and Disease.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020
    Review
  14. Article
  15. MicroRNA dysregulation in lung injury: the role of the miR-26a/EphA2 axis in regulation of endothelial permeability.American journal of physiology. Lung cellular and molecular physiology · 2018
    Article
  16. Article
  17. Article
  18. Neuroprotective strategies for retinal disease.Progress in retinal and eye research · 2018
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Pawan K VohraDept. of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Guggenheim 1334, 200 First St. S.W., Rochester, MN 55905, USA.
Luke H Hoeppner
Gunisha Sagar
Shamit K Dutta
Sanjay Misra
Rolf D Hubmayr
Debabrata Mukhopadhyay
Mayo Clinic · USUniversity Radiology · US

Funding

Distinct Pathways of VPF/VEGF ReceptorsR01HL070567 · NHLBI · MAYO CLINIC ROCHESTER · PI MUKHOPADHYAY, DEBABRATA · 2002 to 2014
$4.7M
Regulatory Pathways and Role of VPF/VEGF in Renal CancerR01CA078383 · NCI · MAYO CLINIC ROCHESTER · PI MUKHOPADHYAY, DEBABRATA · 2004 to 2019
$4.5M
The Neurotransmitter dopamine and angiogenesisR01HL072178 · NHLBI · MAYO CLINIC ROCHESTER · PI MUKHOPADHYAY, DEBABRATA · 2003 to 2007
$1.5M
Tumor Microenvironment/Angiogenesis Training GrantT32CA148073 · NCI · MAYO CLINIC ROCHESTER · PI MC NIVEN, MARK A. · 2010 to 2014
$1.2M
REGULATORY PATHWAYS AND ROLE OF VPF/VEGF IN RENAL CANCERR29CA078383 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI MUKHOPADHYAY, DEBABRATA · 1998 to 2002
$383k
NCI NIH HHS CA78383NCI NIH HHS R01 CA078383NCI NIH HHS T32 CA148073NHLBI NIH HHS HL072178NHLBI NIH HHS HL70567NHLBI NIH HHS R01 HL070567
6 · The paper itself

Abstract

The neurotransmitter dopamine and its dopamine receptor D2 (D2DR) agonists are known to inhibit vascular permeability factor/vascular endothelial growth factor (VEGF)-mediated angiogenesis and vascular permeability. Lung injury is a clinical syndrome associated with increased microvascular permeability. However, the effects of dopamine on pulmonary edema, a phenomenon critical to the pathophysiology of both acute and chronic lung injuries, have yet to be established. Therefore, we sought to determine the potential therapeutic effects of dopamine in a murine model of lipopolysaccharide (LPS)-induced acute lung injury (ALI). Compared with sham-treated controls, pretreatment with dopamine (50 mg/kg body wt) ameliorated LPS-mediated edema formation and lowered myeloperoxidase activity, a measure of neutrophil infiltration. Moreover, dopamine significantly increased survival rates of LPS-treated mice, from 0-75%. Mechanistically, we found that dopamine acts through the VEGF-VEGFR2 axis to reduce pulmonary edema, as dopamine pretreatment in LPS-treated mice resulted in decreased serum VEGF, VEGFR2 phosphorylation, and endothelial nitric oxide synthase phosphorylation. We used D2DR knockout mice to confirm that dopamine acts through D2DR to block vascular permeability in our lung injury model. As expected, a D2DR agonist failed to reduce pulmonary edema in D2DR(-/-) mice. Taken together, our results suggest that dopamine acts through D2DR to inhibit pulmonary edema-associated vascular permeability, which is mediated through VEGF-VEGFR2 signaling and conveys protective effects in an ALI model.

Indexed as

Acute Lung InjuryAnimalsCapillary PermeabilityDopamineDopamine AntagonistsLipopolysaccharidesMaleMiceMice, Inbred BALB CMice, Inbred C57BLMice, KnockoutNeovascularization, PhysiologicNeutrophil InfiltrationNeutrophilsNitric Oxide SynthaseNitric Oxide Synthase Type IIIDopamineDopamine AntagonistsLipopolysaccharidesNitric Oxide SynthaseNitric Oxide Synthase Type IIIPeroxidaseReceptors, Dopamine D2Vascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2

Identifiers

PMID22003095
PMCPMC3349364
OpenAlexW2029226303

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.